'Collaboration Opportunities with Takeda' Recruiting Companies for Bosanjin-Takeda Acceleration Program

The Korea Health Industry Development Institute announced on the 8th that it will hold a public recruitment for the '2023 KHIDI-Takeda Acceleration Program,' which provides opportunities for open innovation collaboration with global pharmaceutical companies for domestic companies possessing excellent technology.

Co-hosted by KHIDI and Takeda Pharmaceutical, this program was established to activate open innovation through network building and collaboration between domestic innovative companies and Takeda. It is conducted by discovering domestic pharmaceutical and bio companies with innovative technologies and capabilities in Takeda's areas of interest, providing research funding along with mentorship opportunities from Takeda's new drug development experts.

The recruitment fields are Oncology and Neuroscience. Any domestic pharmaceutical or bio company with excellent technology in these fields can participate. Specific eligibility criteria can be found in the guidelines on the website. Applications must be submitted with required documents, including the application form, through the online registration site by the 4th of next month.

Among the applying companies, up to four will be selected in the first round through document evaluation, followed by a final announcement evaluation in February next year. Up to two companies finally selected will receive research funding worth 15 million yen (approximately 140 million KRW) and a one-year mentorship opportunity from Takeda's new drug development experts.

Kim Yong-woo, Head of the Pharmaceutical and Bio Industry Division at KHIDI, said, “We have created an opportunity to discover promising domestic companies together with Takeda. We hope many companies with excellent technological capabilities will participate.”

This content was produced with the assistance of AI translation services.